These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 33717139)

  • 1. The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies.
    González-Navajas JM; Fan DD; Yang S; Yang FM; Lozano-Ruiz B; Shen L; Lee J
    Front Immunol; 2021; 12():625783. PubMed ID: 33717139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects.
    Li C; Jiang P; Wei S; Xu X; Wang J
    Mol Cancer; 2020 Jul; 19(1):116. PubMed ID: 32680511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer.
    Wang T; Zhou Q; Zeng H; Zhang H; Liu Z; Shao J; Wang Z; Xiong Y; Wang J; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Chang Y; Wang X; Xu J
    Cancer Immunol Immunother; 2020 Sep; 69(9):1855-1867. PubMed ID: 32367308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?
    Liu J; Zhang B; Zhang G; Shang D
    Front Immunol; 2024; 15():1345838. PubMed ID: 38449875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting post-translational modifications of Foxp3: a new paradigm for regulatory T cell-specific therapy.
    Riaz F; Huang Z; Pan F
    Front Immunol; 2023; 14():1280741. PubMed ID: 37936703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy.
    John P; Pulanco MC; Galbo PM; Wei Y; Ohaegbulam KC; Zheng D; Zang X
    Nat Commun; 2022 May; 13(1):2506. PubMed ID: 35523809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition.
    Singh R; Srivastava P; Manna PP
    Med Oncol; 2024 Jan; 41(2):59. PubMed ID: 38238513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulating Treg stability to improve cancer immunotherapy.
    Kang JH; Zappasodi R
    Trends Cancer; 2023 Nov; 9(11):911-927. PubMed ID: 37598003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting tumor-infiltrating tregs for improved antitumor responses.
    Qin D; Zhang Y; Shu P; Lei Y; Li X; Wang Y
    Front Immunol; 2024; 15():1325946. PubMed ID: 38500876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.
    Lax BM; Palmeri JR; Lutz EA; Sheen A; Stinson JA; Duhamel L; Santollani L; Kennedy A; Rothschilds AM; Spranger S; Sansom DM; Wittrup KD
    Proc Natl Acad Sci U S A; 2023 Aug; 120(31):e2300895120. PubMed ID: 37487077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Assessment of the Tumor-Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer.
    Ravensbergen CJ; Polack M; Roelands J; Crobach S; Putter H; Gelderblom H; Tollenaar RAEM; Mesker WE
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targeting of regulatory T cells in cancer.
    Shan F; Somasundaram A; Bruno TC; Workman CJ; Vignali DAA
    Trends Cancer; 2022 Nov; 8(11):944-961. PubMed ID: 35853825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses.
    Heller S; Glaeske S; Gluske K; Paul J; Böhme A; Janzer A; Roider HG; Montebaur A; Nicke B; Lesche R; von Ahsen O; Politz O; Liu N; Gorjánácz M
    Clin Exp Med; 2023 Dec; 23(8):5445-5461. PubMed ID: 37935952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basic principles of tumor-associated regulatory T cell biology.
    Savage PA; Malchow S; Leventhal DS
    Trends Immunol; 2013 Jan; 34(1):33-40. PubMed ID: 22999714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective.
    Le DT; Jaffee EM
    Cancer Res; 2012 Jul; 72(14):3439-44. PubMed ID: 22761338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy.
    Huppert LA; Green MD; Kim L; Chow C; Leyfman Y; Daud AI; Lee JC
    Cell Mol Immunol; 2022 Jan; 19(1):33-45. PubMed ID: 34417572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel GARP humanized mouse model for efficacy assessment of GARP-targeting therapies.
    Guo J; Niu Z; Lv R; Yuan J; Zhang Z; Guan X; Li D; Zhang H; Zhao A; Feng J; Liu D; Zhou X; Gong J
    Int Immunopharmacol; 2024 Mar; 130():111782. PubMed ID: 38442579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review.
    Li Y; Zhang C; Jiang A; Lin A; Liu Z; Cheng X; Wang W; Cheng Q; Zhang J; Wei T; Luo P
    J Transl Med; 2024 Mar; 22(1):293. PubMed ID: 38509593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology.
    DiNatale RG; Hakimi AA; Chan TA
    Hum Mol Genet; 2020 Oct; 29(R2):R214-R225. PubMed ID: 33029628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies.
    Chen M; Hu S; Li Y; Jiang TT; Jin H; Feng L
    Signal Transduct Target Ther; 2020 Nov; 5(1):270. PubMed ID: 33214545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.